ESTRO 2025 - Abstract Book

S757

Clinical - CNS

ESTRO 2025

Conclusion: Adjuvant chemotherapy with temozolomide significantly improves survival in patients with low-grade gliomas, particularly when administered for six or more months. This effect is observed across both astrocytoma and oligodendroglioma subtypes, underscoring the importance of prolonged adjuvant treatment in optimizing outcomes.

Keywords: TEMOZOLOMIDE, Grade II GLIOMA, ADJUVANT Therapy

4342

Digital Poster International Multicenter Evaluation of Limbic System Coverage in Radiation Treatment Planning for High Grade Glioma Lara Caglayan 1 , Christina Leitzen 1 , Fabian Kugel 1 , Shari Wiegreffe 1 , Tugba Tekin 1 , Jean-Francois Daisne 2 , Laila König 3 , Rami El Shafie 4 , Cas Dejonckheere 1 , Dennis Akuamoa-Boateng 5 , Bartlomiej Tomasik 6 , Luis Moreno Sánchez 7 , Redouane Fouassi 8 , Beatrice Anghel 9 , Kynann Aninditha 10 , Parham Alaei 11 , Hussein Elsayed 12 , Milos Grujic 13 , Sweet Ping Ng 14 , Samet Özcalkap 15 , Mojtaba Barzegar 16 , Hulya Ozdemir 17 , Banu Atalar 18 , Eleni Gkika 1 , Youness Nour 19 1 Radiation Oncology, University hospital Bonn, Bonn, Germany. 2 Radiation Oncology, UZ Leuven, Leuven, Belgium. 3 Radiation Oncology, University hospital Heidelberg, Heidelberg, Germany. 4 Radiation Oncology, University hospital